Board approves Q1 FY27 unaudited financial results

Results View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+4.8%Reaction day

₹22.30

prior close

₹24.70

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.4%+4.4% vs market

Pharmaceuticals peers, median of 165sector-0.6%+5.4% vs sector

On the reaction day the stock moved 4.4 pts more than Nifty Microcap 250 and 5.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.9

10m

-0.0

15m

-2.8

30m

-2.8

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+4.8+0.4+4.4-0.6+5.4

Next day

+1.1+0.5+0.6-0.3+1.4

+2.9+0.6+2.3-0.7+3.6

+3.1+0.7+2.4-1.4+4.6

+3.1+1.1+2.0-1.1+4.2

-1.3+0.5-1.8-2.0+0.7

+2.2+1.3+0.9-1.4+3.7

15d

+9.6+0.5+9.1-1.0+10.6

+4.2-0.8+5.1-0.4+4.6

+14.3-0.9+15.2-3.2+17.5

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 165Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Beryl Drugs board met on 11 Aug 2026 and approved the unaudited financial results for Q1 ended 30 June 2026. The limited review report by auditors was also taken on record. Books of accounts will be maintained at the registered office in Indore. No specific financial numbers were disclosed in this filing.

Likely market impact

Routine quarterly compliance filing. No material business action or change affecting shareholders was disclosed in this board outcome.